Sandra Peiró
Head of the Chromatin Dynamics in Cancer Group
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Evaluation of RAD51 scores in CCA_PDXs and CCA patients. (A) RAD51 scores of CCA_PDXs and their matched originating biopsy samples. (B) RAD51 scores evaluated in PDX85 (IDH1mut) treated as for Figure 4C.
Year:
2025
Growth of cells derived from CCA_PDXs in the 3D ex vivo culture system. (A) Representative bright-field images of cells derived from indicated CCA_PDXs and cultured ex vivo. Images are from days 0, 3, 7, and 10. Scale bar, 1 mm.
Year:
2025
Histopathologic characterization of CCA_PDXs. (A) Histologic and immunohistochemical images of CCA_PDXs. H&E staining, and immunohistochemical staining of KRT19 (CCA marker) and HepPar1 (HCC marker) were shown. CCA_PDX samples were collected at passage 1 (PDX41, PDX96, PDX118, PDX123, PDX132, and PDX133) or passage 2 (PDX58, PDX62, PDX67, PDX68.2, PDX75, PDX75.2, PDX78, PDX84, PDX85, PDX104, PDX119, and PDX120). Scale bar, 250 µm.
Year:
2025
Absence of PARP inhibitor efficacy in IDH1mut, ARID1Amut, or BAP1mut CCA_PDXs. (A) Dose-response curves of niraparib for a panel of tumoroids derived from CCA_PDXs. Cell viability was determined using Cell Titer-Glo assay 7 days after the treatment initiation. Data are mean ± s.d. from independent biological replicates. PDX41, n=3; PDX78, n=3; PDX85, n=6; PDX75, n=2; PDX75.2, n=2; PDX118, n=3; PDX133, n=3. (B) Half-maximal inhibitory concentration (IC50) of niraparib in tumoroids derived from CCA_PDXs. (C) Representative images of immunohistochemical staining for a cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX85 cells treated as for Fig 4C. (D) Representative images of immunohistochemical staining for cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX78 treated as for Fig 4D. Scale bar, 250 µm.
Year:
2025
Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric protein products are indicated.
Year:
2025
Collaborators (13)
Anthony Turpin
Centre Hospitalier Régional Universitaire de Lille
Joaquin Arribas
Research Director
Hospital del Mar
Ana Vivancos
Principal Investigator
Vall d'Hebron Institute of Oncology
ENRIQUE JAVIER ARENAS LAHUERTA
Institute for Research in Biomedicine
Winona Oliveros
KTH Royal Institute of Technology
Cindy Neuzillet
PU PH
Université de Versailles Saint-Quentin-en-Yvelines
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Marta Mele
Group leader
Barcelona Supercomputing Center
Oscar Pozo
Miguel Servet II
Institut Hospital del Mar d'Investigacions Mèdiques
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
Paolo Nuciforo
Head
Vall d´Hebron Institut d´Oncologia
Violeta Serra
Group Leader
Vall d'Hebron Institute of Oncology
TIAN TIAN
Vall d'Hebron Institute of Oncology
Make your next move.
Prepare your application
Review drafts before you send them.